Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer.

Due to the small sample size in this single-institution setting, some of our results did not reach statistical significance; however, the data are promising and warrant further investigation in a multicenter setting.

also in 111,027 other papers